SGD Pharma will present its range of products and services, including its platform Sealian, an internal treatment that enhances the performance of moulded glass vials, on its booth B55 & B59 at Pharmapack.
Absci Corporation and Owkin have announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.
Kindeva Drug Delivery and Emervax has announced an exclusive partnership to co-develop a solution for the administration of vaccines targeting a variety of emerging viruses.
Astraveus SAS, the Benchtop Cell Factory company, has announced the "first ever successful" end-to-end production of CAR-T cells within a microfluidic benchtop system.
FUJIFILM Diosynth Biotechnologies has announced an expansion of its operations, a move that marks a pivotal moment in its journey as a leader in pharmaceuticals.
The success of the UK’s energy transition will rely on collaboration between businesses to maintain a robust supply chain, a global energy specialist has warned following the launch of its latest research.
Mytos has entered into a manufacturing collaboration with Aspen Neuroscience to automate the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease.
23andMe Holding has announced the launch of Discover23, a new research offering enabling authorised collaborators to securely access to the power and diversity of the 23andMe research cohort.
Antag Therapeutics, a biopharmaceutical company pioneering novel treatments for obesity, has announced the appointment of Joerg Moeller, MD, PhD, as chief executive officer, effective immediately.
Pharmapack Europe & CPHI have outlined key trends for pharma in 2025, highlighting the return of funding liquidity—via increased VC investments and PE capital for M&A.
Join thousands of industry professionals at INTERPHEX, the premier pharmaceutical and biotechnology event taking place 1-3 April 2025, at the Javits Center in NYC.
